Clinical Trial Update: Salivary Oxytocin as a Biomarker of Psychedelic Treatment

View source ↗

Summary

A University of Geneva-led trial is investigating whether salivary oxytocin can serve as a biomarker for psychedelic-assisted treatment in major depressive diso…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Major Depressive Disorder

Snippet

Sponsor: University of Geneva, Switzerland | Conditions: Major Depressive Disorder (MDD) | Status: ENROLLING_BY_INVITATION